American Society of Hematology

ASH is committed to helping practicing hematologists provide quality care to patients, continue their professional development, and enhance their knowledge and expertise.

Guidelines and Quality Care

Resources to help practicing hematologists improve the quality
of care provided to patients

Drug Resources

Newly approved therapies and access information on hematologic drugs

Consult a Colleague

Service that provides advice on clinical questions in one to two days

Professional Development

Services to support hematologists with continuing medical education and recertification

Clinical Priorities

Resources to help hematologists understand federal programs, policy developments, and relevant issues affecting clinical practice

ASH Practice Update

Email newsletter highlighting the Society's latest educational offerings and developments impacting clinicians

View all Ask the Hematologist
  • FDA Approves Axicabtagene Ciloleucel for Large B-Cell Lymphoma

    On October 18, 2017, the U.S. Food and Drug Administration granted regular approval to axicabtagene ciloleucel (YESCARTA™, Kite Pharma, Inc.) for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high-grade B-cell lymphoma, and DLBCL arising from follicular lymphoma.

  • FDA Simplifies IRB Requirements for Individual Patient Expanded Access

    On October 3, 2017, the U.S. Food and Drug Administration (FDA) announced updates to three final guidance documents, including Form FDA 3926 and its instructions, to simplify Institutional Review Board (IRB) review requirements for physicians seeking to treat an individual patient with an investigational drug under expanded access. The updates allow for a waiver of the requirement for review and approval at a convened IRB meeting if the physician instead obtains concurrence by the IRB chairperson (or a designated IRB member) before treatment use begins.

  • FDA Grants Accelerated Approval to Copanlisib for Relapsed Follicular Lymphoma

    On September 14, 2017, the U.S. Food and Drug Administration granted accelerated approval to copanlisib (ALIQOPA™, Bayer HealthCare Pharmaceuticals Inc.) for the treatment of adult patients with relapsed follicular lymphoma who have received at least two prior systemic therapies.

  • FDA Approves Gemtuzumab Ozogamicin for CD33-Positive AML

    On September 1, 2017, the U.S. Food and Drug Administration approved gemtuzumab ozogamicin (Mylotarg, Pfizer Inc.) for the treatment of newly-diagnosed CD33-positive acute myeloid leukemia (AML) in adults and for treatment of relapsed or refractory CD33-positive AML in adults and in pediatric patients 2 years and older.

View all FDA alerts
View all policy news
back to top